AustralieFrV1, Main, Exploration, bibRecord, 00CD79

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Identifieur interne : 00CD79 ( Main/Exploration ); précédent : 00CD78; suivant : 00CD80

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Auteurs : Charles M. Beasley Jr [États-Unis] ; Susan H. Hamilton [États-Unis] ; Ann Marie Crawford [États-Unis] ; Mary Anne Dellva [États-Unis] ; Gary D. Tollefson [États-Unis] ; Pierre V. Tran [États-Unis] ; Olivier Blin [France] ; Jean-Noel Beuzen [États-Unis, Autriche]

Source :

European Neuropsychopharmacology [ 0924-977X ] ; 1997.

RBID : ISTEX:1F946544B3FE5F3B8A850215D8446490E5C38F69

English descriptors

Abstract

Abstract: A 6-week acute phase of an international 1-year double-blind study was conducted comparing three dose ranges of olanzapine (5±2.5 mg/day, 10±2.5 mg/day, and 15±2.5 mg/day) with a fixed dose of olanzapine (1.0 mg/day) and with a dose range of haloperidol (15±5 mg/day) in the treatment of 431 patients with schizophrenia. The purpose was to determine whether olanzapine demonstrated a dose-related ability to decrease overall psychopathology with minimal associated extrapyramidal symptoms in patients with schizophrenia. The high-dose olanzapine group showed statistically significantly greater improvement in overall psychopathology based on mean change in the CGI Severity score and statistically significantly greater improvement in positive psychotic symptoms based on mean change in both the BPRS positive score and the PANSS positive score compared with the 1.0-mg/day olanzapine group. Analyses indicated that an increasing dose–response curve was observed across the range of all olanzapine dose groups. Acute extrapyramidal syndromes were reported less frequently among all olanzapine groups compared with the haloperidol group. Endpoint mean change on both the Simpson-Angus Scale and the Barnes Akathisia Scale reflected improvement for all olanzapine treatment groups compared with worsening for the haloperidol group. Olanzapine was associated with weight gain but did not appear to have any clinically meaningful effect on vital signs. Although olanzapine was associated with some increase in prolactin concentrations, increases were transient, occurred less often, and were of lesser magnitude than those observed with haloperidol.

Url:

https://api.istex.fr/document/1F946544B3FE5F3B8A850215D8446490E5C38F69/fulltext/pdf

DOI: 10.1016/S0924-977X(96)00392-6

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000599
to stream Istex, to step Curation: 000599
to stream Istex, to step Checkpoint: 002420
to stream Main, to step Merge: 00DE82
to stream Main, to step Curation: 00CD79

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial</title>
<author><name sortKey="Beasley Jr, Charles M" sort="Beasley Jr, Charles M" uniqKey="Beasley Jr C" first="Charles M" last="Beasley Jr">Charles M. Beasley Jr</name>
</author>
<author><name sortKey="Hamilton, Susan H" sort="Hamilton, Susan H" uniqKey="Hamilton S" first="Susan H" last="Hamilton">Susan H. Hamilton</name>
</author>
<author><name sortKey="Crawford, Ann Marie" sort="Crawford, Ann Marie" uniqKey="Crawford A" first="Ann Marie" last="Crawford">Ann Marie Crawford</name>
</author>
<author><name sortKey="Dellva, Mary Anne" sort="Dellva, Mary Anne" uniqKey="Dellva M" first="Mary Anne" last="Dellva">Mary Anne Dellva</name>
</author>
<author><name sortKey="Tollefson, Gary D" sort="Tollefson, Gary D" uniqKey="Tollefson G" first="Gary D" last="Tollefson">Gary D. Tollefson</name>
</author>
<author><name sortKey="Tran, Pierre V" sort="Tran, Pierre V" uniqKey="Tran P" first="Pierre V" last="Tran">Pierre V. Tran</name>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
</author>
<author><name sortKey="Beuzen, Jean Noel" sort="Beuzen, Jean Noel" uniqKey="Beuzen J" first="Jean-Noel" last="Beuzen">Jean-Noel Beuzen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1F946544B3FE5F3B8A850215D8446490E5C38F69</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1016/S0924-977X(96)00392-6</idno>
<idno type="url">https://api.istex.fr/document/1F946544B3FE5F3B8A850215D8446490E5C38F69/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000599</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000599</idno>
<idno type="wicri:Area/Istex/Curation">000599</idno>
<idno type="wicri:Area/Istex/Checkpoint">002420</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002420</idno>
<idno type="wicri:doubleKey">0924-977X:1997:Beasley Jr C:olanzapine:versus:haloperidol</idno>
<idno type="wicri:Area/Main/Merge">00DE82</idno>
<idno type="wicri:Area/Main/Curation">00CD79</idno>
<idno type="wicri:Area/Main/Exploration">00CD79</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial</title>
<author><name sortKey="Beasley Jr, Charles M" sort="Beasley Jr, Charles M" uniqKey="Beasley Jr C" first="Charles M" last="Beasley Jr">Charles M. Beasley Jr</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Hamilton, Susan H" sort="Hamilton, Susan H" uniqKey="Hamilton S" first="Susan H" last="Hamilton">Susan H. Hamilton</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crawford, Ann Marie" sort="Crawford, Ann Marie" uniqKey="Crawford A" first="Ann Marie" last="Crawford">Ann Marie Crawford</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dellva, Mary Anne" sort="Dellva, Mary Anne" uniqKey="Dellva M" first="Mary Anne" last="Dellva">Mary Anne Dellva</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tollefson, Gary D" sort="Tollefson, Gary D" uniqKey="Tollefson G" first="Gary D" last="Tollefson">Gary D. Tollefson</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tran, Pierre V" sort="Tran, Pierre V" uniqKey="Tran P" first="Pierre V" last="Tran">Pierre V. Tran</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Timone University, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Beuzen, Jean Noel" sort="Beuzen, Jean Noel" uniqKey="Beuzen J" first="Jean-Noel" last="Beuzen">Jean-Noel Beuzen</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center 0538</wicri:regionArea>
<wicri:noRegion>Lilly Corporate Center 0538</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>1 The Olanzapine E003 Study Group; UG Ahlfors, Finland; E Alvarez, Spain; J Andersen, Denmark; T Andersen, Sweden; SK Asserson, Norway; JL Ayuso, Spain; JM Azorin, France; RW Bamber, England; HP Belmaker, Israel; G Besancon, France; L Bogren, Sweden; SW Boyes, South Africa; J Brabrand, Norway; J Dalery, France; G Darcourt, France; F Daubenton, South Africa; JA Den Boer, Netherland; M Dietzel, Austria; A Elizur, Israel; RA Emsley, South Africa; MS Ewart-Smith, South Africa; S Feeney, England; ML Figueira, Portugal; RR O'Flynn, England; J Frannson, Sweden; CA Gagiano, South Africa; OB Gallhofer, Germany; MT Gastpar, Germany; J Giner, Spain; AS Hale, England; LA Heikkila, Finland; G Hellinga, Netherlands; H Hippius, Germany; NA Keks, Australia; J Kristiansen, Norway; P Konig, Austria; C Leal, Spain; JJ López-Ibor, Spain; IT Marcea, Germany; I Mateo, Spain; OP Mehtonen, Finland; HJ Moller, Germany; H Munitz, Israel; ME Nordstrom, Finland; JC Peuksens, Belgium; H Pfolz, Austria; MH Roest, Netherlands; JL Roos, South Africa; E Swoboda, Austria; H Schubert, Austria; T Schulte, Germany; JC Scotto, France; AJ Tholen, Netherlands; IS Thomsen, Denmark; J Tignol, France; L Van Audenrode, Belgium; WH Wessels, South Africa; B Wistedt, Sweden; HG Zapotoczky</wicri:regionArea>
<wicri:noRegion>Sweden; HG Zapotoczky</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Neuropsychopharmacology</title>
<title level="j" type="abbrev">NEUPSY</title>
<idno type="ISSN">0924-977X</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1997">1997</date>
<biblScope unit="volume">7</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="125">125</biblScope>
<biblScope unit="page" to="137">137</biblScope>
</imprint>
<idno type="ISSN">0924-977X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0924-977X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abbreviation</term>
<term>Acute exacerbation</term>
<term>Acute phase</term>
<term>Acute treatment period</term>
<term>Adverse events</term>
<term>Akathisia</term>
<term>Antipsychotic</term>
<term>Antipsychotic agent</term>
<term>Atypical</term>
<term>Atypical antipsychotic</term>
<term>Baseline</term>
<term>Beasley</term>
<term>Benzodiazepine</term>
<term>Bprs</term>
<term>Clozapine</term>
<term>Discontinuation</term>
<term>Dos</term>
<term>Dose range</term>
<term>Elevation</term>
<term>Endpoint</term>
<term>Eosinophil counts</term>
<term>European neuropsychopharmacology</term>
<term>Extrapyramidal</term>
<term>Greater improvement</term>
<term>Group improvement</term>
<term>Hal5haloperidol</term>
<term>Hal5haloperidol treatment range</term>
<term>Haloperidol</term>
<term>Haloperidol treatment group</term>
<term>Laboratory analytes</term>
<term>Last observation</term>
<term>Linear relationship</term>
<term>Lorazepam equivalents</term>
<term>Maximum case</term>
<term>Negative scores</term>
<term>Negative symptoms</term>
<term>Negative syndrome scale</term>
<term>Neuropsychopharmacology</term>
<term>Olanzapine</term>
<term>Olanzapine dose</term>
<term>Olanzapine treatment groups</term>
<term>Other treatment groups</term>
<term>Panss</term>
<term>Parkinsonism</term>
<term>Placebo</term>
<term>Present study</term>
<term>Prolactin</term>
<term>Psychopathology</term>
<term>Psychopharmacology</term>
<term>Rating scale</term>
<term>Receptor</term>
<term>Reference range</term>
<term>Schizophrenia</term>
<term>Score improvement</term>
<term>Score visitwise change</term>
<term>Sd5standard deviation</term>
<term>Serum prolactin</term>
<term>Severity score</term>
<term>Study entry</term>
<term>Superior improvement</term>
<term>Syndrome</term>
<term>Total score</term>
<term>Treatment group</term>
<term>Treatment groups</term>
<term>Treatment range</term>
<term>Typical antipsychotics</term>
<term>Upper limit</term>
<term>Wong</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Abbreviation</term>
<term>Acute exacerbation</term>
<term>Acute phase</term>
<term>Acute treatment period</term>
<term>Adverse events</term>
<term>Akathisia</term>
<term>Antipsychotic</term>
<term>Antipsychotic agent</term>
<term>Atypical</term>
<term>Atypical antipsychotic</term>
<term>Baseline</term>
<term>Beasley</term>
<term>Benzodiazepine</term>
<term>Bprs</term>
<term>Clozapine</term>
<term>Discontinuation</term>
<term>Dos</term>
<term>Dose range</term>
<term>Elevation</term>
<term>Endpoint</term>
<term>Eosinophil counts</term>
<term>European neuropsychopharmacology</term>
<term>Extrapyramidal</term>
<term>Greater improvement</term>
<term>Group improvement</term>
<term>Hal5haloperidol</term>
<term>Hal5haloperidol treatment range</term>
<term>Haloperidol</term>
<term>Haloperidol treatment group</term>
<term>Laboratory analytes</term>
<term>Last observation</term>
<term>Linear relationship</term>
<term>Lorazepam equivalents</term>
<term>Maximum case</term>
<term>Negative scores</term>
<term>Negative symptoms</term>
<term>Negative syndrome scale</term>
<term>Neuropsychopharmacology</term>
<term>Olanzapine</term>
<term>Olanzapine dose</term>
<term>Olanzapine treatment groups</term>
<term>Other treatment groups</term>
<term>Panss</term>
<term>Parkinsonism</term>
<term>Placebo</term>
<term>Present study</term>
<term>Prolactin</term>
<term>Psychopathology</term>
<term>Psychopharmacology</term>
<term>Rating scale</term>
<term>Receptor</term>
<term>Reference range</term>
<term>Schizophrenia</term>
<term>Score improvement</term>
<term>Score visitwise change</term>
<term>Sd5standard deviation</term>
<term>Serum prolactin</term>
<term>Severity score</term>
<term>Study entry</term>
<term>Superior improvement</term>
<term>Syndrome</term>
<term>Total score</term>
<term>Treatment group</term>
<term>Treatment groups</term>
<term>Treatment range</term>
<term>Typical antipsychotics</term>
<term>Upper limit</term>
<term>Wong</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: A 6-week acute phase of an international 1-year double-blind study was conducted comparing three dose ranges of olanzapine (5±2.5 mg/day, 10±2.5 mg/day, and 15±2.5 mg/day) with a fixed dose of olanzapine (1.0 mg/day) and with a dose range of haloperidol (15±5 mg/day) in the treatment of 431 patients with schizophrenia. The purpose was to determine whether olanzapine demonstrated a dose-related ability to decrease overall psychopathology with minimal associated extrapyramidal symptoms in patients with schizophrenia. The high-dose olanzapine group showed statistically significantly greater improvement in overall psychopathology based on mean change in the CGI Severity score and statistically significantly greater improvement in positive psychotic symptoms based on mean change in both the BPRS positive score and the PANSS positive score compared with the 1.0-mg/day olanzapine group. Analyses indicated that an increasing dose–response curve was observed across the range of all olanzapine dose groups. Acute extrapyramidal syndromes were reported less frequently among all olanzapine groups compared with the haloperidol group. Endpoint mean change on both the Simpson-Angus Scale and the Barnes Akathisia Scale reflected improvement for all olanzapine treatment groups compared with worsening for the haloperidol group. Olanzapine was associated with weight gain but did not appear to have any clinically meaningful effect on vital signs. Although olanzapine was associated with some increase in prolactin concentrations, increases were transient, occurred less often, and were of lesser magnitude than those observed with haloperidol.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Provence-Alpes-Côte d'Azur</li>
</region>
<settlement><li>Marseille</li>
</settlement>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Beasley Jr, Charles M" sort="Beasley Jr, Charles M" uniqKey="Beasley Jr C" first="Charles M" last="Beasley Jr">Charles M. Beasley Jr</name>
</noRegion>
<name sortKey="Beuzen, Jean Noel" sort="Beuzen, Jean Noel" uniqKey="Beuzen J" first="Jean-Noel" last="Beuzen">Jean-Noel Beuzen</name>
<name sortKey="Crawford, Ann Marie" sort="Crawford, Ann Marie" uniqKey="Crawford A" first="Ann Marie" last="Crawford">Ann Marie Crawford</name>
<name sortKey="Dellva, Mary Anne" sort="Dellva, Mary Anne" uniqKey="Dellva M" first="Mary Anne" last="Dellva">Mary Anne Dellva</name>
<name sortKey="Hamilton, Susan H" sort="Hamilton, Susan H" uniqKey="Hamilton S" first="Susan H" last="Hamilton">Susan H. Hamilton</name>
<name sortKey="Tollefson, Gary D" sort="Tollefson, Gary D" uniqKey="Tollefson G" first="Gary D" last="Tollefson">Gary D. Tollefson</name>
<name sortKey="Tran, Pierre V" sort="Tran, Pierre V" uniqKey="Tran P" first="Pierre V" last="Tran">Pierre V. Tran</name>
</country>
<country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
</region>
</country>
<country name="Autriche"><noRegion><name sortKey="Beuzen, Jean Noel" sort="Beuzen, Jean Noel" uniqKey="Beuzen J" first="Jean-Noel" last="Beuzen">Jean-Noel Beuzen</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00CD79 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00CD79 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1F946544B3FE5F3B8A850215D8446490E5C38F69
   |texte=   Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri